Literature DB >> 10484955

Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder.

M Maj1, R Pirozzi, A M Formicola, A Tortorella.   

Abstract

OBJECTIVE: This study tested the reliability and validity of four definitions of rapid cycling.
METHOD: Two trained psychiatrists, using the Schedule for Affective Disorders and Schizophrenia, independently assessed 210 patients with bipolar disorder. They checked whether each patient met four definitions of rapid cycling: one consistent with DSM-IV criteria, one waiving criteria for duration of affective episodes, one waiving such criteria and requiring at least one switch from mania to depression or vice versa during the reference year, and one waiving duration criteria and requiring at least 8 weeks of fully symptomatic affective illness during the reference year. The interrater reliability was calculated by Cohen's kappa statistic. Patients who met each definition according to both psychiatrists were compared to those who did not meet any definition (nonrapid-cycling group) on demographic and clinical variables. All patients were followed up for 1 year.
RESULTS: Kappa values were 0.93, 0.73, 0.75, and 0.80, respectively, for the four definitions of rapid cycling. The groups meeting the second and third definitions included significantly more female and bipolar II patients than did the nonrapid-cycling group. Those two groups also had the lowest proportion of patients with a favorable lithium prophylaxis outcome and the highest stability of the rapid-cycling pattern on follow-up. The four groups of rapid-cycling patients did not differ significantly among themselves on any of the assessed variables.
CONCLUSIONS: The expression "rapid cycling" encompasses a spectrum of conditions. The DSM-IV definition, although quite reliable, covers only part of this spectrum, and the conditions that are excluded are very typical in terms of key validators and are relatively stable over time.

Entities:  

Mesh:

Year:  1999        PMID: 10484955     DOI: 10.1176/ajp.156.9.1421

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  8 in total

1.  Diagnosis and treatment of rapidly cycling bipolar disorder.

Authors:  M Maj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

2.  Comparison of treatment outcome using two definitions of rapid cycling in subjects with bipolar II disorder.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Robert J DeRubeis
Journal:  Bipolar Disord       Date:  2017-02-03       Impact factor: 6.744

Review 3.  Current concepts in rapid cycling bipolar disorder.

Authors:  M D Shelton; J R Calabrese
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 4.  Rapid cycling bipolar disorder: clinical characteristics and treatment options.

Authors:  William Coryell
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Rapid cycling bipolar disease: new concepts and treatments.

Authors:  S L Dubovsky
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 5.285

6.  Rapid cycling bipolar disorders in primary and tertiary care treated patients.

Authors:  Tomas Hajek; Margaret Hahn; Claire Slaney; Julie Garnham; Joshua Green; Martina Růzicková; Peter Zvolský; Martin Alda
Journal:  Bipolar Disord       Date:  2008-06       Impact factor: 6.744

7.  Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.

Authors:  L Lorenzo-Luaces; J D Amsterdam; I Soeller; R J DeRubeis
Journal:  Acta Psychiatr Scand       Date:  2016-01-24       Impact factor: 6.392

8.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.